| 摘要 |
<p>The present invention provides (I) wherein X is α-CH2OR1 when A is α-hydro, A and B together are ethylene, and C and D together are ethylene, β-CH¿2OR?1, or -CO-; R is -H or n-butylsulfonoyl; R1 is R provided that at least one of R and R1 must be n-butylsulfonoyl; R2 is -H, α- or β-hydroxy, or α- or β-n-butylsulfonoyl; A is (a) or (b); B is (c) or (d); C is -CH¿2? or (b); and D is -CH2 or (b), methods of inhibiting estrogen deficient pathologies, and pharmaceutical formulations.</p> |
